These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 26237486)

  • 1. Importance of Beta Cell Function for the Treatment of Type 2 Diabetes.
    Saisho Y
    J Clin Med; 2014 Aug; 3(3):923-43. PubMed ID: 26237486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. β-cell dysfunction: Its critical role in prevention and management of type 2 diabetes.
    Saisho Y
    World J Diabetes; 2015 Feb; 6(1):109-24. PubMed ID: 25685282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beta-cell function and mass in type 2 diabetes.
    Larsen MO
    Dan Med Bull; 2009 Aug; 56(3):153-64. PubMed ID: 19728971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Replacing SUs with incretin-based therapies for type 2 diabetes mellitus: challenges and feasibility.
    Knop FK; Holst JJ; Vilsbøll T
    IDrugs; 2008 Jul; 11(7):497-501. PubMed ID: 18600596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pancreatic fat content is associated with β-cell function and insulin resistance in Chinese type 2 diabetes subjects.
    Lu T; Wang Y; Dou T; Xue B; Tan Y; Yang J
    Endocr J; 2019 Mar; 66(3):265-270. PubMed ID: 30700664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Defining the role of repaglinide in the management of type 2 diabetes mellitus: a review.
    Johansen OE; Birkeland KI
    Am J Cardiovasc Drugs; 2007; 7(5):319-35. PubMed ID: 17953471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of glucagon secretion.
    Young A
    Adv Pharmacol; 2005; 52():151-71. PubMed ID: 16492545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Insulin resistance and islet beta cell function in type 2 diabetes mellitus and non alcoholic fatty liver disease.].
    Li FP; Zhang SQ; Wang F; Huang YQ; Fu ZZ; Yan L
    Zhonghua Nei Ke Za Zhi; 2009 Nov; 48(11):940-3. PubMed ID: 20079327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changing the Concept of Type 2 Diabetes: Beta Cell Workload Hypothesis Revisited.
    Saisho Y
    Endocr Metab Immune Disord Drug Targets; 2019; 19(2):121-127. PubMed ID: 30173655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment Strategy for Type 2 Diabetes with Obesity: Focus on Glucagon-like Peptide-1 Receptor Agonists.
    Ji Q
    Clin Ther; 2017 Jun; 39(6):1244-1264. PubMed ID: 28526416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic Modifications Associated with the Pathogenesis of Type 2 Diabetes Mellitus.
    Hossan T; Kundu S; Alam SS; Nagarajan S
    Endocr Metab Immune Disord Drug Targets; 2019; 19(6):775-786. PubMed ID: 30827271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preservation of β-cell function: the key to diabetes prevention.
    DeFronzo RA; Abdul-Ghani MA
    J Clin Endocrinol Metab; 2011 Aug; 96(8):2354-66. PubMed ID: 21697254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Applicability of adipose-derived mesenchymal stem cells in treatment of patients with type 2 diabetes.
    Qi Y; Ma J; Li S; Liu W
    Stem Cell Res Ther; 2019 Aug; 10(1):274. PubMed ID: 31455405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preserving insulin secretion in Type 2 diabetes mellitus.
    Tibaldi J
    Expert Rev Endocrinol Metab; 2008 Mar; 3(2):147-159. PubMed ID: 30764089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Signaling pathways and intervention for therapy of type 2 diabetes mellitus.
    Cao R; Tian H; Zhang Y; Liu G; Xu H; Rao G; Tian Y; Fu X
    MedComm (2020); 2023 Jun; 4(3):e283. PubMed ID: 37303813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Role of insulin resistance and β cell function in the development of newly diagnosed type 2 diabetes].
    Chen X; Su M; Wang C; Wu Z; Li S; Ying X; Wei G; Fu C; Jiang Q
    Wei Sheng Yan Jiu; 2015 Nov; 44(6):881-6. PubMed ID: 26738376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EADSG Guidelines: Insulin Therapy in Diabetes.
    Silver B; Ramaiya K; Andrew SB; Fredrick O; Bajaj S; Kalra S; Charlotte BM; Claudine K; Makhoba A
    Diabetes Ther; 2018 Apr; 9(2):449-492. PubMed ID: 29508275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple defects in counterregulation of hypoglycemia in modestly advanced type 2 diabetes mellitus.
    Israelian Z; Szoke E; Woerle J; Bokhari S; Schorr M; Schwenke DC; Cryer PE; Gerich JE; Meyer C
    Metabolism; 2006 May; 55(5):593-8. PubMed ID: 16631434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early and intensive therapy for management of hyperglycemia and cardiovascular risk factors in patients with type 2 diabetes.
    Dailey G
    Clin Ther; 2011 Jun; 33(6):665-78. PubMed ID: 21704233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liraglutide and the preservation of pancreatic β-cell function in early type 2 diabetes: the LIBRA trial.
    Retnakaran R; Kramer CK; Choi H; Swaminathan B; Zinman B
    Diabetes Care; 2014 Dec; 37(12):3270-8. PubMed ID: 25249651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.